keyword
MENU ▼
Read by QxMD icon Read
search

Low density lipoprotein

keyword
https://www.readbyqxmd.com/read/28644091/prevention-of-cardiovascular-disease-in-patients-with-familial-hypercholesterolaemia-the-role-of-pcsk9-inhibitors
#1
Ivan Pećin, Merel L Hartgers, G Kees Hovingh, Ricardo Dent, Željko Reiner
Familial hypercholesterolaemia is an autosomal dominant inherited disorder characterised by elevated low-density lipoprotein cholesterol levels and consequently an increased risk of atherosclerotic cardiovascular disease (ASCVD). Familial hypercholesterolaemia is relatively common, but is often underdiagnosed and undertreated. Cardiologists are likely to encounter many individuals with familial hypercholesterolaemia; however, patients presenting with premature ASCVD are rarely screened for familial hypercholesterolaemia and fasting lipid levels are infrequently documented...
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28644038/critical-review-on-the-analytical-techniques-for-the-determination-of-the-oldest-statin-atorvastatin-in-bulk-pharmaceutical-formulations-and-biological-fluids
#2
K S Kokilambigai, R Seetharaman, K S Lakshmi
Statins are a group of medicines that can help to lower the level of low-density-lipoprotein(LDL) cholesterol "bad cholesterol" in the blood. Having a high level of LDL cholesterol is potentially dangerous, as it can lead to a hardening and narrowing of arteries (atherosclerosis) and cardiovascular disease (CVD), Atorvastatin is one of the oldest member of the statin family and is used in the treatment of dyslipidemia and the prevention of cardiovascular disease. Atorvastatin was first made in August 1985 and from 1996 to 2012 under the trade name Lipitor, atorvastatin became the world's best selling drug...
June 23, 2017: Critical Reviews in Analytical Chemistry
https://www.readbyqxmd.com/read/28643478/critical-role-of-tnf-inhibition-in-combination-therapy-for-elderly-mice-with-atherosclerosis
#3
Kyung-Yeon Park, Tae-Hwe Heo
We have previously shown that the combination of pravastatin and sarpogrelate is synergistically beneficial for atherosclerosis. In this study, we investigated whether the pravastatin-sarpogrelate combination was sufficient for treatment in an old mouse model of atherosclerosis or if additional intervention would be needed to address the newly included aging factor and its complex pathophysiological impact on the atherosclerogenic state. We added an anti-TNF biologic to the combination treatment cocktail because of the known pathologic roles of TNF in the aging process...
June 23, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28643240/pcsk9-inhibitors-treating-the-right-patients-in-daily-practice
#4
REVIEW
Peta King, Stephen J Nicholls
PURPOSE OF REVIEW: Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as a novel approach to low-density lipoprotein cholesterol (LDL-C) lowering. The potential role of PCSK9 inhibitors in clinical practice will be reviewed. RECENT FINDINGS: Clinical trials have demonstrated that PCSK9 inhibitors produce robust LDL-C lowering when administered either as monotherapy or in combination with statins. This provides the opportunity to achieve effective lipid lowering in familial hypercholesterolemia, patients with either established atherosclerotic cardiovascular disease or high risk primary prevention and an important opportunity to treat patients with statin intolerance...
August 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28642826/elucidation-of-the-role-of-lectin-like-oxldl-receptor-1-in-the-metabolic-responses-of-macrophages-to-human-oxldl
#5
Danielle W Kimmel, William P Dole, David E Cliffel
Atherogenesis is the narrowing of arteries due to plaque build-up that results in cardiovascular disease that can lead to death. The macrophage lectin-like oxidized LDL receptor-1 (LOX-1), also called the oxidized low-density lipoprotein receptor 1 (OLR1), is currently thought to aid in atherosclerotic disease progression; therefore metabolic studies have potential to both provide mechanistic validation for the role of LOX-1 in disease progression and provide valuable information regarding biomarker strategies and clinical imaging...
2017: Journal of Lipids
https://www.readbyqxmd.com/read/28642237/mediator-1-is-atherosclerosis-protective-by-regulating-macrophage-polarization
#6
Liang Bai, Zhao Li, Qianwei Li, Hua Guan, Sihai Zhao, Ruihan Liu, Rong Wang, Jin Zhang, Yuzhi Jia, Jianglin Fan, Nanping Wang, Janardan K Reddy, John Y-J Shyy, Enqi Liu
OBJECTIVE: MED1 (mediator 1) interacts with transcription factors to regulate transcriptional machinery. The role of MED1 in macrophage biology and the relevant disease state remains to be investigated. APPROACH AND RESULTS: To study the molecular mechanism by which MED1 regulates the M1/M2 phenotype switch of macrophage and the effect on atherosclerosis, we generated MED1/apolipoprotein E (ApoE) double-deficient (MED1(ΔMac)/ApoE(-)(/-)) mice and found that atherosclerosis was greater in MED1(ΔMac)/ApoE(-/-) mice than in MED1(fl/fl)/ApoE(-/-) littermates...
June 22, 2017: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/28642135/light-is-increased-in-patients-with-coronary-disease-and-regulates-inflammatory-response-and-lipid-metabolism-in-oxldl-induced-thp-1-macrophages
#7
Xiaomei Yuan, Yonglin Gu, Xiaoyu Lai, Qing Gu
Inflammation is critical for the progression of hyperlipidemia. Although the exact mechanism through which inflammation affects hyperlipidemia is not very clear, evidence suggests that the tumor necrosis factor superfamily member 14 (TNFSF14/LIGHT)LIGHT might regulate lipid metabolism. In this study we investigated the expression of LIGHT in patients with different stages of coronary disease. The expression of lipid metabolism-related enzymes and inflammation-related proteins were further explored in oxidized low-density lipoproteins (oxLDL)-induced THP-1 macrophages...
June 19, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28641782/high-prevalence-of-apolipoprotein-b-dyslipoproteinemias-in-non-alcoholic-fatty-liver-disease-the-lifelines-cohort-study
#8
Karlijn J Nass, Eline H van den Berg, Klaas Nico Faber, Tim C M A Schreuder, Hans Blokzijl, Robin P F Dullaart
OBJECTIVE: Cardiovascular disease (CVD) is a major adverse consequence of non-alcoholic fatty liver disease (NAFLD). The association of NAFLD with various apolipoprotein B (apoB) dyslipoproteinemias is unclear. We determined the prevalence of specific apoB dyslipoproteinemias in subjects with suspected NAFLD. METHODS: This study was conducted among 22,865 fasting adults living in the northern part of the Netherlands (Lifelines Cohort Study). Six apoB dyslipoproteinemias were defined using an algorithm derived from apoB, total cholesterol and triglycerides...
July 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28641570/1h-post-load-blood-glucose-in-the-identification-of-proatherogenic-cardiometabolic-profile-in-obesity
#9
Djordje S Popovic, Dragana Tomic-Naglic, Milena Mitrovic, Zeljko Zivanovic, Bojan Vukovic, Edita Stokic
BACKGROUND AND AIM: Current data show that 1h oral glucose tolerance test (OGTT) blood glucose (1h-BG) might identify persons at increased risk of developing type 2 diabetes and cardiovascular diseases more precisely than fasting blood glucose (FBG) and 2h OGTT blood glucose (2h-BG). The aim of study was to determine whether is justified to use 1h-BG, instead of traditional blood glucose measurements, in cardiometabolic profiling of obese individuals. METHOD: Cross-sectional study enrolled 60 obese individuals without previous history of diabetes and other cardiometabolic disorders...
June 13, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/28641153/lipoprotein-a-and-coronary-atheroma-progression-rates-during-long-term-high-intensity-statin-therapy-insights-from-saturn
#10
Rishi Puri, Christie M Ballantyne, Ron C Hoogeveen, Mingyuan Shao, Philip Barter, Peter Libby, M John Chapman, Raimund Erbel, Benoit J Arsenault, Joel S Raichlen, Steven E Nissen, Stephen J Nicholls
BACKGROUND & AIMS: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle that associates with major adverse cardiovascular events (MACE). We examined relationships between Lp(a) measurements and changes in coronary atheroma volume following long-term maximally-intensive statin therapy in coronary artery disease patients. METHODS: Study of coronary atheroma by intravascular ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN) used serial intravascular ultrasound measures of coronary atheroma volume in patients treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months...
June 15, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28640711/effects-of-season-and-postmortem-changes-on-blood-analytes-in-pyrenean-chamois-rupicapra-pyrenaica
#11
Asta Tvarijonaviciute, Ignasi Marco, Rafaela Cuenca, Santiago Lavín, Josep Pastor
Our objectives were to evaluate the effects of the 1) season, and 2) postmortem changes on serum biochemistries related with metabolism in Pyrenean chamois (Rupicapra pyrenaica pyrenaica). Serum samples from 98 animals obtained from 2009 to 2012 were included. To investigate seasonal influences on blood parameters, the Pyrenean chamois were captured in drive-nets during the feed abundant (FA; n=32) and food deficient (FD; n=35) seasons. To evaluate the possible differences in biochemistry analytes when sampling live or dead animals, we used serum samples from 32 captured animals and 31 dead animals (obtained during controlled hunting) in the FA season...
June 22, 2017: Journal of Wildlife Diseases
https://www.readbyqxmd.com/read/28639974/an-evaluation-of-cardioprevent-a-technology-enabled-health-behavior-change-program-for-the-global-reduction-of-cardiovascular-risk
#12
Stephanie A Prince, Robert D Reid, Andrew L Pipe, Lisa A McDonnell
PURPOSE OF REVIEW: Cardiovascular diseases (CVDs) are the leading cause of mortality globally. Primary CVD prevention programs have the potential to improve risk factor profiles and, ultimately, the risk of developing CVD. The present study presents an evaluation of CardioPrevent, a global cardiovascular risk reduction program. RECENT FINDINGS: Of the 478 participants enrolled in the CardioPrevent program, 308 and 236 had complete 6-month and 12-month data, respectively at the time of evaluation...
July 20, 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/28639572/relation-of-biochemical-parameters-with-flow-mediated-dilatation-in-patients-with-metabolic-syndrome
#13
Nurver Turfaner Sipahioglu, Barıs Ilerigelen, Zeynep B Gungor, Gulsel Ayaz, Hakan Ekmekci, Cigdem Bayram Gurel, Gunay Can, Huseyin Sonmez, Turgut Ulutin, Fikret Sipahioglu
BACKGROUND: Metabolic syndrome (MetS) is one of the high cardiovascular (CV) situations. Endothelial dysfunction, which is a common finding in patients with MetS, is related with increased CV risk. In patients with MetS, the effect of the major CV risk factors, not included in the MetS definition, on endothelial dysfunction is not well known. The aim of this study was to determine the effect of major CV risk factors such as gender, smoking, family history, and biochemical parameters on endothelial dysfunction in patients with MetS...
July 5, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28639183/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-and-its-inhibitors-a-review-of-physiology-biology-and-clinical-data
#14
REVIEW
Ashwin Durairaj, Alberto Sabates, Jonathan Nieves, Brian Moraes, Seth Baum
Atherosclerotic cardiovascular disease (ASCVD) remains the number one killer in the western world. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and ezetimibe has been shown to reduce the risk of cardiovascular events. Now, proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mabs) are available for high-risk individuals with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy but requiring greater LDL-C reduction. PCSK9 mab outcome trial results from the Further Cardiovascular Outcomes Research with PCSK9 Inhibitions in Subjects with Elevated Risk (FOURIER) study, which was presented at the American College of Cardiology in March 2017, which demonstrated a decrease of 15% in primary and 20% secondary end points over a 2-year period [1••]...
August 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28638704/lipid-and-hyperglycemia-factors-in-first-ever-penetrating-artery-infarction-a-comparison-between-different-subtypes
#15
Shaoyang Sun, Yanqiang Wang, Yuge Wang, Xuejiao Men, Jian Bao, Xueqiang Hu, Zhengqi Lu
BACKGROUND: The pathogenesis and progression of branch atheromatous disease (BAD), which differs from lipohyalinotic degeneration (LD), remains controversial. Few studies have investigated the lipid indices and glycometabolism status factors for BAD in first-ever penetrating artery infarction (PAI). METHODS: We retrospectively examined acute stroke patients with PAI admitted within 3 days after stroke. All patients underwent diffusion weight magnetic resonance imaging (DWI) and magnetic resonance angiography (MRA) and/or computed tomography angiography (CTA)...
June 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28638000/effectiveness-of-workplace-exercise-supervised-by-a-physical-therapist-among-nurses-conducting-shift-work-a-randomized-controlled-trial
#16
Ryutaro Matsugaki, Satoshi Kuhara, Satoru Saeki, Ying Jiang, Ryoma Michishita, Masanori Ohta, Hiroshi Yamato
OBJECTIVES: This study aimed to evaluate the effectiveness of supervised exercise among nurses conducting shift work for health promotion. METHODS: A total of 30 healthy female nurses conducting shift work participated in this study and they were randomly assigned to one of the following 2 groups: The supervised exercise group (SG; participants exercised under the supervision of a physical therapist (PT)) and the voluntary exercise group (VG; participants exercised without supervision)...
June 20, 2017: Journal of Occupational Health
https://www.readbyqxmd.com/read/28637783/paradoxical-suppression-of-atherosclerosis-in-the-absence-of-microrna-146a
#17
Henry S Cheng, Rickvinder Besla, Angela Li, Zhiqi Chen, Eric A Shikatani, Maliheh Nazari-Jahantigh, Adel Hammoutène, My-Anh Nguyen, Michele Geoffrion, Lei Cai, Nadiya Khyzha, Tong Li, Sonya A MacParland, Mansoor Husain, Myron I Cybulsky, Chantal M Boulanger, Ryan E Temel, Andreas Schober, Katey J Rayner, Clinton Robbins, Jason E Fish
Rationale: Inflammation is a key contributor to atherosclerosis. MicroRNA-146a (miR-146a) has been identified as a critical brake on pro-inflammatory NF-κB signalling in several cell types, including endothelial cells and bone marrow-derived cells. Importantly, miR-146a expression is elevated in human atherosclerotic plaques, and polymorphisms in the miR-146a pre-cursor have been associated with risk of coronary artery disease. Objective: To define the role of endogenous miR-146a during atherogenesis. Methods and Results: Paradoxically, Low-density lipoprotein receptor (Ldlr)(-/-) mice deficient in miR-146a develop less atherosclerosis, despite having highly elevated levels of circulating pro-inflammatory cytokines...
June 21, 2017: Circulation Research
https://www.readbyqxmd.com/read/28637722/cross-sectional-surveillance-study-to-phenotype-lorry-drivers-sedentary-behaviours-physical-activity-and-cardio-metabolic-health
#18
Veronica Varela-Mato, Orlagh O'Shea, James A King, Thomas Yates, David J Stensel, Stuart Jh Biddle, Myra A Nimmo, Stacy A Clemes
OBJECTIVES: Elevated risk factors for a number of chronic diseases have been identified in lorry drivers. Unhealthy lifestyle behaviours such as a lack of physical activity (PA) and high levels of sedentary behaviour (sitting) likely contribute to this elevated risk. This study behaviourally phenotyped UK lorry drivers' sedentary and non-sedentary behaviours during workdays and non-workdays and examined markers of drivers cardio-metabolic health. SETTING: A transport company from the East Midlands, UK...
June 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/28637586/soluble-lr11-associates-with-aortic-root-calcification-in-asymptomatic-treated-male-patients-with-familial-hypercholesterolemia
#19
Ranitha Vongpromek, Sven Bos, Gert-Jan R Ten Kate, Hideaki Bujo, Meizi Jiang, Koen Nieman, Wolfgang Schneider, Jeanine E Roeters van Lennep, Adrie J M Verhoeven, Eric J G Sijbrands, Monique T Mulder
BACKGROUND AND AIMS: Despite statin treatment, a high prevalence of severe vascular calcification is found in patients with familial hypercholesterolemia (FH). We assessed the relation between the circulating soluble form of low-density lipoprotein receptor relative with 11 ligand-binding repeats (sLR11), a risk factor for cardiovascular disease, and vascular calcification in asymptomatic statin-treated heterozygous FH patients. METHODS: In 123 asymptomatic heterozygous FH patients (age 40-69 years), aortic root (ARC), aortic valve (AVC) and coronary artery calcification (CAC) were determined with CT-based calcium scoring expressed in Agatston units...
June 9, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/28637418/anti-inflammatory-effect-of-crocus-sativus-on-the-serum-cytokines-levels-in-subjects-with-metabolic-syndrome-a-randomized-double-blind-placebo-controlled-trial
#20
Tayebe Kermani, Maedeh Zebarjadi, Hassan Mehrad-Majd, Seyed-Reza Mirhafez, Maryam Shemshian, Faezeh Ghasemi, Elham Mohammadzadeh, Seyed Hadi Mousavi, Abdolreza Norouzy, Toktam Moghiman, Akram Sadeghi, Gordon Ferns, Amir Avan, Elaheh Mahdipour, Majid Ghayour-Mobarhan
BACKGROUND/AIMS: A growing body of evidence supports an important role of inflammatory-cytokines in development and progression of metabolic-syndrome (MetS), which explain, at least in part, its relationship with an increased cardiovascular-risk. Several studies have reported the therapeutic-impact of crocus-sativus in preclinical/clinical setting. Here we have explored the effects of crocus-sativus, saffron, on the modulation of twelve serum cytokines in subjects with MetS in a randomized control trial...
June 21, 2017: Current Clinical Pharmacology
keyword
keyword
337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"